Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness
2015 (English)In: Frontiers in Neurology, ISSN 1664-2295, E-ISSN 1664-2295, Vol. 6, UNSP 18Article in journal (Refereed) Published
Background: Fatigue is a frequent symptom in multiple sclerosis (MS) and often interrelated with depression and sleep disorders making symptomatic treatment decisions difficult. In the single-arm, observational phase IVTYNERGY study, relapsing remitting MS patients showed a clinically meaningful decrease in fatigue over 1 year of treatment with natalizumab. Objective: To evaluate whether fatigue improvement might be directly linked to improved depression and day-time sleepiness. Methods: Patients were assessed regarding fatigue, depression, and day-time sleepiness. The relation between changes of the two latter symptoms and changes in fatigue was analyzed. Results: After 1 year of natalizumab treatment, the majority of patients (>92%) remained stable or improved in total, motor, and cognitive fatigue. Proportion of patients without depression increased by 17% while proportions of mildly depressed patients or patients with potential major depression decreased by 5 and 12%, respectively. Proportion of patients classified as not being sleepy increased by 13% while proportions of sleepy and very sleepy patients decreased by 11 and 2%, respectively. Most importantly, improved depression and sleepiness were significantly related to improved fatigue. Conclusion: Our findings highlight the importance of patient-reported outcomes in identifying potential benefits of drug treatment beyond its well-established effects on disease activity and disability progression.
Place, publisher, year, edition, pages
2015. Vol. 6, UNSP 18
fatigue, multiple sclerosis, treatment response, depression, sleepiness
IdentifiersURN: urn:nbn:se:umu:diva-111773DOI: 10.3389/fneur.2015.00018ISI: 000363764700001PubMedID: 25755648ScopusID: 2-s2.0-84926286469OAI: oai:DiVA.org:umu-111773DiVA: diva2:873224